PKUMDL-WQ-2201

Novel Selective Allosteric Inhibitor of PHGDH and Serine Synthesis with Anti-tumor Activity, binding to site II

What is PKUMDL-WQ-2201?

• PKUMDL-WQ-2201 is a small molecule allosteric inhibitor of phosphoglycerate dehydrogenase (PHGDH). Forward 2000

• More specifically, it is a negative allosteric modulator (i.e. it binds at a non-active site and downregulates PHGDH activity) Cell 

• In enzyme inhibition assays, its IC₅₀ for PHGDH is about 35.7 μM 

Target & Pathway: PHGDH and Serine Biosynthesis

• PHGDH (3-phosphoglycerate dehydrogenase) is the first enzyme in the de novo serine synthesis pathway, converting 3-phosphoglycerate (a glycolytic intermediate) to 3-phosphohydroxypyruvate. Cell+3ijbs.com+3PMC+3

• Because serine is a precursor for many biosynthetic processes (nucleotides, proteins, lipids, one-carbon metabolism), many cancer cells, especially those with PHGDH overexpression or amplification, rely on serine synthesis for proliferation. ijbs.com+5PMC+5

• By inhibiting PHGDH, PKUMDL-WQ-2201 suppresses de novo serine synthesis, which can limit the metabolic support for tumor cell growth. PMC+

Mechanism / Binding Mode

• PKUMDL-WQ-2201 is non-competitive with respect to NAD⁺ and substrate (i.e. it does not bind in the active or cofactor pocket) — rather, it acts allosterically. 

• The inhibitor is proposed to bind to an “allosteric site II”, located in the substrate-binding domain, which influences domain movements necessary for catalysis. PMC+3Forward 2000 (Oxon) Ltd+3Cell+3

• Structural modeling (or docking) suggests it forms hydrogen bonds with residues such as K57, T59, T56, stabilizing the enzyme in an inactive conformation by restricting motions of rigid domains required for catalysis. Cell+3ijbs.com+3Cell+3

• Because of this binding, the enzyme is prevented from closing its catalytic conformation fully, thus reducing its activity. Cell+3

Biological / Cellular Effects

• In cancer cell lines, PKUMDL-WQ-2201 shows dose-dependent suppression of cell viability in various models. Cell

• In xenograft mouse tumor models, it has been observed to inhibit tumor growth when combined with cancer cells that are dependent on PHGDH.

• In one recent study of breast cancer lines, PKUMDL-WQ-2201 inhibited viability of MCF-7 (ER+ cells) but had limited effect on MDA-MB-231 (a triple-negative line) under certain conditions, suggesting cell context dependency. PMC

• The inhibitor effectively reduces the flux through serine synthesis, thereby interfering with downstream metabolic pathways tied to proliferation and survival. PMC+4Cell

Strengths, Limitations, & Considerations

Strengths / advantages:

• As an allosteric inhibitor, PKUMDL-WQ-2201 avoids competition with high intracellular concentrations of cofactors like NAD⁺, which can hamper competitive inhibitors’ efficacy. PMC+2Cell+2

• It offers a route to selectively target tumors with PHGDH overexpression or dependency on de novo serine synthesis, potentially sparing normal tissues that rely less on this pathway. Forward 2000 (Oxon) Ltd+4PMC+4ijbs.com+4

• In vivo data (in mice) support its capacity to impair tumor growth, which is promising as a proof-of-concept. PMC

Limitations / challenges:

• The IC₅₀ is moderate (≈ 35.7 µM), which is not especially potent for many drug development standards. PMC

• Because serine can also be imported from extracellular sources or synthesized via alternative pathways, tumors might bypass inhibition by compensatory metabolic flux. PMC+3ijbs.com+3PMC+3

• The context specificity means not all cancer cell types will respond uniformly. As seen in the MCF-7 vs MDA-MB-231 contrast, sensitivity varies. PMC

• Potential toxicity or off-target effects are not yet fully characterized in humans or large animal models — systemic inhibition of serine production could affect non-tumor tissues.

• Because it is a research compound (not clinical grade), its pharmacokinetics, bioavailability, stability, and safety in humans remain unproven.